The article, titled “SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors”, was published in Cellular & Molecular Immunology. This study co-expressed SMAD7, a suppressor of TGF-β signaling, with a HER2-targeted chimeric antigen receptor (CAR) in engineered T cells.
SMAD7 substantially reduced the production of inflammatory cytokines by antigen-primed CAR-T cells. Mechanistically, SMAD7 downregulated TGF-β receptor I and abrogated the interplay between the TGF-β and NF-κB pathways in CAR-T cells.
SMAD7 co-expression also enhanced CAR-T-cell infiltration and persistent activation in patient-derived tumor organoids.
Therefore, this study demonstrated the feasibility of SMAD7 co-expression as a novel approach to improve the efficacy and safety of CAR-T-cell therapy for solid tumors.
BMKGENE provides transcriptome sequencing and bioinformatics analysis services for this study.
If you would like to learn more about this study, access this link. For more information on our sequencing and bioinformatics services, you can talk to us here.
Post time: Jul-18-2024